Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Teerlink

Internal Medicine San Francisco, CA Medical Doctor

NPI 1851309975 CMS profile 38190

4150 Clement St, Sfvamc; Cardiology 111C, San Francisco, CA 94121

Open in the dashboard

General payments

$819,023

330 records reported · program years 2019–2025

Research payments

$126,988

Paid to them · 18 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$63 paid to institutions, not to them · program year 2019

Through program year 2025, John Teerlink of San Francisco, CA is reported in the CMS Open Payments database as having received $819,023 across 330 general payments and $126,988 in research payments paid to them. Separately, studies naming them as principal investigator received $63 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,473 16
2025 Research $8,375 1
2024 General $115,420 36
2023 General $94,938 40
2023 Research $22,375 2
2022 General $21,416 12
2022 Research $28,900 3
2021 General $92,769 20
2021 Research $29,035 5
2020 General $351,819 113
2020 Research $14,393 4
2019 General $82,189 93
2019 Research $23,911 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Teerlink
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Teerlink were reported at $60,473. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Teerlink Internal Medicine median Middle half National median
2019 $82,189 $159 $48–$570 $163
2020 $351,819 $119 $33–$402 $114
2021 $92,769 $135 $37–$521 $132
2022 $21,416 $141 $42–$496 $149
2023 $94,938 $149 $45–$519 $160
2024 $115,420 $154 $47–$537 $164
2025 $60,473 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $415,758 134 payments
  2. AstraZeneca UK Limited $103,277 27 payments
  3. Amgen Inc. $36,952 38 payments
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $32,793 5 payments
  5. Eli Lilly and Company $26,000 12 payments
  6. Regeneron Pharmaceuticals, Inc. $17,900 19 payments
  7. Edwards Lifesciences Corporation $14,159 9 payments
  8. E.R. Squibb & Sons, L.L.C. $13,821 14 payments
  9. Retrophin, Inc. $13,052 3 payments
  10. AstraZeneca AB $12,893 3 payments
  11. Other $132,418 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $587,269 141 payments
  2. Travel and Lodging $181,584 81 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,941 4 payments
  4. Honoraria $12,100 3 payments
  5. Food and Beverage $7,130 101 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $388,467 125 payments
  2. EMPAGLIFLOZIN $27,079 3 payments
  3. JARDIANCE Diabetes $24,733 5 payments
  4. ENTRESTO $11,088 1 payment
  5. JARDIANCE Diabetes $10,800 5 payments
  6. OPTIMIZER Cardiovascular Device $9,495 7 payments
  7. OPTIMIZER Cardiovascular Device $9,495 7 payments
  8. LUTONIX $7,500 1 payment
  9. FARXIGA $6,380 8 payments
  10. MK-1242 $5,650 2 payments
  11. Other $29,978 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $88,685 11 payments
  2. Medtronic Vascular, Inc. $34,615 4 payments
  3. Eli Lilly and Company $3,600 1 payment
  4. Amgen Inc. $88 2 payments

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record